Sharma NR, Wagle A, Bist M, Panthi B, Pokhrel Dahal R, Rokaya R, Shrestha R, Pokhrel M. Clarithromycin-induced acute liver injury in a patient with positive
Helicobacter pylori: a case report and review of the literature.
Ann Med Surg (Lond) 2023;
85:4629-4632. [PMID:
37663679 PMCID:
PMC10473337 DOI:
10.1097/ms9.0000000000001135]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Accepted: 07/27/2023] [Indexed: 09/05/2023] Open
Abstract
Introduction and importance
While 14-day triple therapy with clarithromycin is a common approach for eradicating Helicobacter pylori infection, it is essential to note that this treatment does not come without potential side effects.
Case presentation
We present the case of a 34-year-old male who presented to the emergency department with severe vomiting and abdominal pain. Subsequent evaluation revealed that the patient had developed drug-induced liver injury (DILI).
Clinical discussion
DILI can cause acute hepatocellular or cholestatic damage, and chronic injury can lead to hepatocellular, cholestatic, vascular, or neoplastic manifestations.
Conclusion
Clinicians should exercise caution and be alert to the potential hepatotoxic effects of medications, especially when initiating triple therapy for H. pylori infection.
Collapse